you are here: HomeNewsWorld

Pfizer to supply US with 100 million more COVID-19 shots by July

The agreement brings the total number of doses to be delivered to the United States to 200 million, allowing for 100 million people to be vaccinated.

December 23, 2020 / 07:14 PM IST

Pfizer Inc will supply the United States with 100 million additional doses of its COVID-19 vaccine by July next year, the US drugmaker said on Wednesday.

The agreement brings the total number of doses to be delivered to the United States to 200 million, allowing for 100 million people to be vaccinated.

Pfizer and German partner BioNTech SE will deliver at least 70 million doses by June 30, with the balance of the 100 million doses to be delivered no later than July 31, the company said.

Follow our LIVE blog for the latest updates on the New COVID strain

The US government will pay $1.95 billion for the additional 100 million doses, bringing the total paid to Pfizer to nearly $4 billion.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The government already has a deal with Pfizer for 100 million doses of the vaccine, which are being rolled out across the country after the shot won emergency use authorization earlier this month.

Pfizer's two-dose shot is one of the two granted emergency approval in the United States, the other being rival Moderna Inc's vaccine based on a similar technology.

The new deal will help the United States bolster its vaccine supply, as it grapples with a nationwide spike in infections that added more than a million new cases in just six days, according to a Reuters tally.

More than 600,000 Americans have received their first COVID-19 vaccine doses as of Monday, according to the Centers for Disease Control and Prevention (CDC).

Follow our full coverage of the coronavirus pandemic here.
Reuters
first published: Dec 23, 2020 07:00 pm

stay updated

Get Daily News on your Browser
Sections